WO2009060865A1 - 医薬組成物及び医薬組成物の製造方法 - Google Patents

医薬組成物及び医薬組成物の製造方法 Download PDF

Info

Publication number
WO2009060865A1
WO2009060865A1 PCT/JP2008/070127 JP2008070127W WO2009060865A1 WO 2009060865 A1 WO2009060865 A1 WO 2009060865A1 JP 2008070127 W JP2008070127 W JP 2008070127W WO 2009060865 A1 WO2009060865 A1 WO 2009060865A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
lymphocyte
cell
cells
types
Prior art date
Application number
PCT/JP2008/070127
Other languages
English (en)
French (fr)
Inventor
Tsuneo Kuramochi
Original Assignee
Tsuneo Kuramochi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsuneo Kuramochi filed Critical Tsuneo Kuramochi
Priority to JP2009540061A priority Critical patent/JP4953403B2/ja
Priority to KR1020107012084A priority patent/KR101299299B1/ko
Publication of WO2009060865A1 publication Critical patent/WO2009060865A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　ＮＫ細胞及びリンパ球の２種類の細胞、又は、ＮＫＴ細胞、ＮＫ細胞及びリンパ球の３種類の細胞が増殖及び活性化した医薬組成物ならびにこれらの医薬組成物の製造方法を提供する。 　抗ヒトＣＤ３モノクローナル抗体と抗ヒトＣＤ１６１モノクローナル抗体が固相化された培養容器内に、末梢血から分離した末梢血リンパ球混合物を、インターロイキン－２を含有するリンパ球培養液と共に収容して培養することにより、ＮＫ細胞及びリンパ球の２種類の細胞、又は、ＮＫＴ細胞、ＮＫ細胞及びリンパ球の３種類の細胞を略同時に、容易に、しかも効率よく増殖及び活性化する。
PCT/JP2008/070127 2007-11-05 2008-11-05 医薬組成物及び医薬組成物の製造方法 WO2009060865A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009540061A JP4953403B2 (ja) 2007-11-05 2008-11-05 がん免疫療法用細胞の製造方法
KR1020107012084A KR101299299B1 (ko) 2007-11-05 2008-11-05 암면역 요법용 세포의 제조방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-287291 2007-11-05
JP2007287291 2007-11-05

Publications (1)

Publication Number Publication Date
WO2009060865A1 true WO2009060865A1 (ja) 2009-05-14

Family

ID=40625753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070127 WO2009060865A1 (ja) 2007-11-05 2008-11-05 医薬組成物及び医薬組成物の製造方法

Country Status (3)

Country Link
JP (1) JP4953403B2 (ja)
KR (1) KR101299299B1 (ja)
WO (1) WO2009060865A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521215A (ja) * 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Ｎｋ細胞の増殖
JP2015502756A (ja) * 2011-12-22 2015-01-29 モガム バイオテクノロジー リサーチ インスティチュート ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物
WO2016013041A1 (ja) * 2014-07-22 2016-01-28 株式会社がん免疫研究所 末梢循環癌細胞の検出方法および検出装置
CN108004210A (zh) * 2017-12-18 2018-05-08 吉林大学 一种大量诱导扩增具有adcc效应的nk细胞的方法
CN111690608A (zh) * 2020-06-19 2020-09-22 珠海贝索细胞科学技术有限公司 一种双抗体联合胸腺肽体外培养nk细胞试剂及试剂盒和培养方法
US11766456B2 (en) 2014-11-26 2023-09-26 GC Cell Corporation Method for culturing natural killer cells using T cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05219945A (ja) * 1992-02-05 1993-08-31 Kawasumi Lab Inc 機能的ｔ細胞亜群の高純度大量培養方法
JP2001314183A (ja) * 2000-02-29 2001-11-13 Japan Science & Technology Corp キラー活性を増強したリンパ球

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05219945A (ja) * 1992-02-05 1993-08-31 Kawasumi Lab Inc 機能的ｔ細胞亜群の高純度大量培養方法
JP2001314183A (ja) * 2000-02-29 2001-11-13 Japan Science & Technology Corp キラー活性を増強したリンパ球

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXLEY, M. ET AL.: "CD161 (NKR-P1A) costimulation of CDld-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains", J EXP MED, vol. 188, no. 5, 1998, pages 867 - 876 *
NORIFUMI YOSHIDA ET AL.: "NKR-P1A (CD161) Monoclonal Kotai o Mochiita Hito Kinogata NKT Saibo Zoshoku Hoho no Kento", NIHON GAN GAKKAI GAKUJUTSU SOKAI KIJI, vol. 64TH, 15 August 2005 (2005-08-15), pages 56 *
NORIKO ISONO ET AL.: "CD3 Kotai Kosoka no Soi ni yoru NK Saibo Zoshokuno no Soi", PROCEEDINGS OF THE JAPANESE CANCER ASSOCIATION, vol. 61ST, 25 August 2002 (2002-08-25), pages 130 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521215A (ja) * 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Ｎｋ細胞の増殖
US8877182B2 (en) 2009-03-26 2014-11-04 Cellprotect Nordic Pharmaceuticals Ab Expansion of NK cells
JP2015502756A (ja) * 2011-12-22 2015-01-29 モガム バイオテクノロジー リサーチ インスティチュート ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物
WO2016013041A1 (ja) * 2014-07-22 2016-01-28 株式会社がん免疫研究所 末梢循環癌細胞の検出方法および検出装置
JP6052756B2 (ja) * 2014-07-22 2016-12-27 株式会社がん免疫研究所 末梢循環癌細胞の検出方法および検出装置
CN106796237A (zh) * 2014-07-22 2017-05-31 株式会社癌症免疫研究所 末梢循环癌细胞的检测方法及检测装置
KR101922322B1 (ko) 2014-07-22 2018-11-26 가부시키가이샤 간멘에키켄큐쇼 말초 순환 암세포의 검출 방법 및 검출 장치
CN106796237B (zh) * 2014-07-22 2018-12-04 株式会社癌症免疫研究所 末梢循环癌细胞的检测装置
US11766456B2 (en) 2014-11-26 2023-09-26 GC Cell Corporation Method for culturing natural killer cells using T cells
CN108004210A (zh) * 2017-12-18 2018-05-08 吉林大学 一种大量诱导扩增具有adcc效应的nk细胞的方法
CN108004210B (zh) * 2017-12-18 2020-09-04 吉林省吉恩致合生物治疗技术有限公司 一种大量诱导扩增具有adcc效应的nk细胞的方法
CN111690608A (zh) * 2020-06-19 2020-09-22 珠海贝索细胞科学技术有限公司 一种双抗体联合胸腺肽体外培养nk细胞试剂及试剂盒和培养方法

Also Published As

Publication number Publication date
JP4953403B2 (ja) 2012-06-13
JPWO2009060865A1 (ja) 2011-03-24
KR20100083838A (ko) 2010-07-22
KR101299299B1 (ko) 2013-08-26

Similar Documents

Publication Publication Date Title
Sarker et al. A review of the role of critical parameters in the design and operation of biogas production plants
Yeshanew et al. Production of biohythane from food waste via an integrated system of continuously stirred tank and anaerobic fixed bed reactors
Chen et al. Effects of ammonia on anaerobic digestion of food waste: process performance and microbial community
WO2009060865A1 (ja) 医薬組成物及び医薬組成物の製造方法
Wang et al. Investigation of anaerobic digestion of Chlorella sp. and Micractinium sp. grown in high-nitrogen wastewater and their co-digestion with waste activated sludge
WO2010013947A3 (ko) 자연살해세포의 증식방법
AU2010207871B2 (en) Integrated system for hydrogen and methane production from industrial organic wastes and biomass
WO2005007800A3 (ja) 抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2008064744A8 (en) A method of preparing polymer dispensed liquid crystal
RU2010125605A (ru) Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
WO2009028631A1 (ja) 角膜内皮細胞接着促進剤
WO2007106523A3 (en) Propagation of primary cells
EP2410043A3 (en) Stem cells culture systems
WO2007044418A3 (en) Cell culture media, kits and methods of use
EP2020433A3 (en) Continuous perfusion bioreactor system
WO2007143104A8 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
MX2009002388A (es) Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos.
WO2006050050A3 (en) Chemically defined media compositions
WO2008136398A1 (ja) 高濃度アミノ酸含有培地を用いた細胞の培養方法
RS50531B (sr) Upotreba podloge za ćelijsku kulturu bez sadržaja seruma za produkciju il-18bp u ćelijama sisara
WO2012058508A3 (en) Methods and systems for the production of hydrocarbon products
WO2008108412A1 (ja) 血清調製方法及び血清調製装置
EA201290391A1 (ru) Способ и система для осахаривания и ферментации сырья из биомассы
WO2011044194A3 (en) Algae processing
WO2011116922A3 (de) Thermoresponsives substrat mit mikrogelen, verfahren zu dessen herstellung und kultivierungsverfahren für biologische zellen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848233

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009540061

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107012084

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 08848233

Country of ref document: EP

Kind code of ref document: A1